Amivantamab Rechallenge Demonstrates Promise in Patients With Left-Sided Metastatic Colorectal Cancer
According to updated results from the OrigAMI-1 trial, amivantamab rechallenge showed promising antitumor activity and lengthened survival end points among patients who underwent rechallenge at least 9 months after EGFR inhibitor treatment.
These data were presented by Dirk Arnold, MD, PhD, Asklepios Tumorzentrum Hamburg, Hamburg, Germany, at the ESMO Gastrointestinal Cancers Congress in Barcelona, Spain.
In this study, 54 patients who experienced disease progression on or after at least 2 to 3 prior lines of anti-EGFR therapy received amivantamab monotherapy. Primary end points included objective response rate (ORR), disease control rate, progression-free survival (PFS), and overall survival (OS). Key efficacy data was reported based on length of time between retreatment (≤2 half-lives, n = 29; >2 half-lives n = 25).
At a median follow-up of 13.7 months, the ORR was 19% and the disease control rate was 72%. Median PFS was 4.6 months and the 6-month PFS rate was 32%. Median OS was 14 months and the 6-month and 12-month OS rates were 74% and 55%, respectively. In patients with a shorter interval between retreatment, the ORR was 7% and the disease control rate was 59%. For those patients, median PFS was 2.8 months and the 6-month PFS rate was 14%. Median OS was 10.4 months and the 6-month and 12-month OS rates were 62% and 44%, respectively. In patients with a longer interval between retreatment, the ORR was 32% and the disease control rate was 88%. Median PFS was 7 months and the 6-month PFS rate was 52%. Median OS was 16.1 months and the 6-month and 12-month OS rates were 88% and 68%, respectively.
“Rechallenge with amivantamab showed promising antitumor activity and longer PFS and OS for [patients] who had at least an ∼9-mo interval between prior EGFRi therapy compared to those with a shorter interval,” concluded Dr Arnold et al.
Source:
Arnold D, Fernandez EE, Van Cutsem E, et al. Rechallenge with amivantamab, an EGFR-MET bispecific antibody, after disease progression on prior EGFR inhibitor in left-sided RAS/BRAF wild-type metastatic colorectal cancer: Updated results from OrigAMI-1. Presented at ESMO Gastrointestinal Cancers Congress. July 2-5, 2025. Abstract 6 MO
